Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Jazz Pharmaceuticals PLC

JAZZ
Current price
109.57 USD -0.43 USD (-0.39%)
Last closed 108.79 USD
ISIN USG508711052
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 718 163 456 USD
Yield for 12 month -17.22 %
1Y
3Y
5Y
10Y
15Y
JAZZ
21.11.2021 - 28.11.2021

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. Address: Waterloo Exchange, Dublin, Ireland, D04 E5W7

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

175.56 USD

P/E ratio

18.439

Dividend Yield

Current Year

+3 834 204 000 USD

Last Year

+3 659 374 000 USD

Current Quarter

+1 023 825 000 USD

Last Quarter

+901 983 000 USD

Current Year

+2 790 343 000 USD

Last Year

+3 118 857 000 USD

Current Quarter

+758 700 000 USD

Last Quarter

+650 766 000 USD

Key Figures JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 423 776 000 USD
Operating Margin TTM 19.48 %
PE Ratio 18.439
Return On Assets TTM 4.29 %
PEG Ratio 0.8133
Return On Equity TTM 10.84 %
Wall Street Target Price 175.56 USD
Revenue TTM 3 909 882 880 USD
Book Value 60.94 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 6.9 %
Dividend Yield
Gross Profit TTM 3 392 249 000 USD
Earnings per share 5.9 USD
Diluted Eps TTM 5.9 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY 64.3 %
Profit Margin 10.1 %

Dividend Analytics JAZZ

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation JAZZ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 18.439
Forward PE 5.7737
Enterprise Value Revenue 2.6929
Price Sales TTM 1.7183
Enterprise Value EBITDA 8.6622
Price Book MRQ 1.7855

Financials JAZZ

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators JAZZ

For 52 weeks

99.06 USD 137.39 USD
50 Day MA 109.74 USD
Shares Short Prior Month 2 035 745
200 Day MA 114.9 USD
Short Ratio 3.28
Shares Short 1 892 100
Short Percent 4.06 %